May 25, 2017
Oxford, UK – 25 May 2017. Oxford Gene Technology (OGT), The Molecular Genetics Company, has made several advances in hybridisation-based target enrichment protocols that now enable researchers to prepare samples for sequencing in just one day. Researchers can now access the high-quality results of hybridisation-based targeted sequencing with a speed comparable to that of amplicon-based approaches.
Read More
May 25, 2017
The IMMY CrAg® LFA (Cryptococcal Antigen Lateral Flow Assay) is the first and only immunochromatographic dipstick assay for the qualitative and semi-quantitative detection of the cryptococcal capsular antigen in serum, plasma and cerebrospinal fluid (CSF).
Read More
May 16, 2017
Belgium, 16 May 2017 – Multiplicom, an Agilent Technologies Company, announced today the extended CE-IVD certification of its BRCA MASTR Plus Dx. This next-generation molecular diagnostic solution uniquely detects both germline* (inherited) and somatic (acquired) mutations in BRCA1 and BRCA2 genes. In combination with the MASTR Reporter, both an analysis software and a quality control tool, it is the one solution for all BRCA mutation testing needs.
Read More
May 08, 2017
SpeciSafe® secondary packaging containers provide a safe, convenient and economical solution for UN3373 compliant mailing of biological and clinical specimens. The extensive range includes solutions for screw cap microtubes, vacuum blood collection tubes, cryovials, Universal and Bijou containers, plus swabs/transport tubes.
Read More
May 08, 2017
Cardiff, UK – 2nd May 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces that it is expanding the distribution of its Procalcitonin LiquiColor® Test into Eastern Europe, Middle East and APAC regions. Procalcitonin (PCT) is a marker for bacterial infection and sepsis, a condition that has grown in awareness in recent years. PCT is now widely recognized as an important adjunct marker in sepsis diagnosis which aids in the differentiation between viral and bacterial infecti...
Read More
May 02, 2017
BBI Solutions is pleased to announce that it has triumphed at the DxMA’s 2017 Dx Creative Awards, winning the New IVD Product Launch (less than $100m) category for the market release of its Morffi™ signal enhancement technology. The awards ceremony (held in New Orleans, USA, on the 30th of April) was an opportunity to celebrate the latest innovations in the diagnostics field ahead of the DxMA Global Marketing Summit on the 1st of May, where BBI’s Dr Neil Polwart was also presenting the compan...
Read More
Apr 24, 2017
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement with Thermo Fisher Scientific, the world leader in serving science. The announcement was made at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna to submit its ResistancePlus MG Test for the detection of Mycoplasma genitalium to the US Food & Drug Administration (FDA).
Read More
Mar 24, 2017
Dr Catharine Sturgeon will be presenting her case for an international effort to align manufacturer’s assays for CA125, CA19-9 and other mucinous markers in a webinar. Organised by BBI Solutions, a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market, the webinar will cover benefits of tumour marker standardisation and discuss how tumour marker standardisation can be improved.
Read More
Feb 16, 2017
Cardiff, UK – 16th February 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces that in a newly published paper [1] its Quo-Test® point-of-care (POC) hemoglobin A1c (HbA1c) analyzer has again been confirmed to meet International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) performance criteria. Using sigma-metrics data modelling, scientists from the European Reference Laboratory for Glycohemoglobin demonstrated that Quo-Test easily met IFCC accepted qu...
Read More
Feb 16, 2017
β-lactamase enzymes inactivate β-lactam antibiotics and render them ineffective for the treatment of clinically-important Gram-negative bacterial infections. Now, two new kits from Streck Inc., available in the UK from Alpha Laboratories Ltd., provide a comprehensive, cost-effective molecular method to detect the most clinically-important β-lactamases that confer resistance to penicillins, cephamycins, and in some cases, carbapenems.
Read More
Page 8 of 9 [8]